Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02588105 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT02588105 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 84 participants.
The verdict
NCT02588105, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether AZD0156 is safe, what is the best dose to give, and how it is processed by the body when given alone or in combination with other agents. The study will also collect some initial information about how effective it is.
Interventions
- DRUG Fluorouracil
- DRUG Olaparib
- DRUG Folinic Acid
- DRUG irinotecan
- DRUG AZD0156
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2015-11-10 |
| Est. Completion | 2022-07-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02588105
The ClinicalTrials.gov registry entry for NCT02588105 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fluorouracil is the first listed.
NCT02588105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02588105 about?
NCT02588105 is a clinical study titled "Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer". The purpose of this study is to determine whether AZD0156 is safe, what is the best dose to give, and how it is processed by the body when given alone or in combination with other agents. The study will also collect some initial information about how effective it is.
What is the current status of trial NCT02588105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2015-11-10. Estimated completion is 2022-07-26.
What interventions are being tested in trial NCT02588105?
The interventions under investigation include: Fluorouracil (DRUG), Olaparib (DRUG), Folinic Acid (DRUG), irinotecan (DRUG), AZD0156 (DRUG).
Who is sponsoring clinical trial NCT02588105?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.